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Background. Paranasal and nasal cavity malignancies are rare tumors that frequently present at advanced stages. Tumor extension
and anatomic complexity pose a challenge for their treatment. Due to their peculiar physical and biological properties particle
radiation therapy, i.e. protons and ions can have a role in their management. We performed a systematic literature review to gather
clinical evidence about their use to treat sinonasal malignancies. Materials and Methods. We searched the browsers PubMed and
Medline as well as speciﬁc journals and conference proceedings. Inclusion criteria were: at least 10 patients, English language,
reporting outcome and/or toxicity data. Results. We found six studies with data on clinical outcome. Carbon and helium ions
were each used in one study, protons in four. Toxicity was speciﬁcally described in ﬁve studies. One reported acute toxicity of
carbon ions, one dealt with brain toxicity from both carbon ions and protons. Three papers reported on visual toxicity: one from
carbon ions, one from protons and one from both. Speciﬁc data were extracted and compared with the most pertinent literature.
Conclusion. Particle radiation therapy is in its early phase of development. Promising results achieved so far must be conﬁrmed in
further studies.
1.Introduction
Paranasal sinus and nasal cavity malignancies are rare with
an incidence rate estimated to range from 0.3 to 3.5 per
100.000 per annum [1, 2]. They account for 3% of head and
neck carcinomas and about 0.5% of all malignant diseases
[3].Squamouscellcarcinomaisthemostcommonhistology;
however, adenocarcinoma, adenoid cystic carcinoma, and
undifferentiated carcinoma are relatively common too [4].
Several other histotypes like malignant melanoma [5], sarco-
ma [6], neuroendocrine tumors, namely, esthesioneuroblas-
toma,sinonasalundiﬀerentiatedcarcinoma,neuroendocrine
carcinoma, and small cell undiﬀerentiated carcinoma [7, 8]
can occur but are uncommon. Diﬀerent incidence rates and
pathologydistributionareobservedindiﬀerentgeographical
areas and they are thought to relate mainly to professional
exposure [1, 2] such as among wood and furniture [1, 2, 9]
workers. Males are usually more frequently aﬀected than
females [1].
Sinonasal malignancies present frequently at advanced
stages due to late symptom onset. This, combined with the
complexregionalanatomyandthepresenceofseveralorgans
at risk (OARs) such as brain and optic structures, poses a
challenge for their best management. The mainstay of treat-
ment is surgery [10]: traditionally a craniofacial approach
[11–13] has been employed. In recent years, in order to
achieve wider resection margins and or to spare signiﬁcant
side eﬀects, craniotomy and endoscopic approaches or their
combination have been tested with encouraging results [14–
16].
Radiation therapy has been employed either as adjuvant
treatment for high-risk cases or as deﬁnitive therapy for un-
resectable disease. No clear evidence exists for a routine use
of chemotherapy, which is administered generally in a case-
by-case scenario [17, 18]. Despite the therapeutic eﬀorts,
results are not completely satisfactory, with overall survival
rates at 5 years ranging from 50% to 67% [19, 20]f o r
combined treatment and from 15% to 38% when radiation
therapy is given as the sole treatment [10, 21]. Furthermore,
side eﬀects associated with the treatment can be signiﬁcant
[22, 23]. The use of highly conformal techniques has2 International Journal of Otolaryngology
demonstrated its feasibility even in advanced stages and has
shown a signiﬁcant reduction of side eﬀects [24].
Particle radiation therapy, that is, protons and heavy
ions, is a relatively new type of radiation therapy that could
enhance the therapeutic ratio for sinonasal malignancies.
Protons and heavy ions share the same characteristic dose
distribution, the so-called Bragg Peak, that is the release
of almost all their energy in a few millimeters at the end
of their path (see Figure 1). This peak is narrow and not
suitable to treat target volumes so it has to be opportunely
spread out, the so-called SOBP-Spread Out-Bragg Peak,
allowing thus the delivery of high doses sparing at the same
time OARs. Comparative treatment planning studies have
demonstrated the robustness of heavy particle generated
plans and showed their advantages over photon plans [25].
Protons have a relative biologic eﬀectiveness (RBE) that
is slightly higher than photons according to some authors
[26], its value being around 1.1, or exactly the same as
photons according to others [27]. Anyhow, the International
Commission on Radiation Units and Measurements (ICRU)
in its 78 report issued in 2007 recommends using a value of
1.1 [28]. More complex is the situation for heavy charged
particles since the RBE is not constant along their path,
but increases with increasing depth, reaching the maximum
at the peak region [29]. RBE is dependent indeed by the
microdosimetric pattern of energy deposition that is, the
Linear Energy Transfer (LET) that increases as they slow
down [30]. The advantage of high LET radiations is that
there is less variation in radiosensitivity during the cell cycle,
less reduction of repair of radiation injury, and lower oxygen
enhancement ratio [31]. From preparatory studies, an RBE
value of 3 for carbon ion was found at the distal part of
the SOPB [32]. In order of taking into account the diﬀerent
RBE of particle radiation therapy, their dose is expressed
in Gy (RBE) that is the product of the physical dose in Gy
multiplied for the speciﬁc RBE [30].
An altered fractionation regimen is any radiotherapy
schedule that diﬀers from the standard delivery of 1.8–
2.0Gy, 5 days a week for an overall treatment time of
about 6-7 weeks. They can be classiﬁed as hyperfractionated,
accelerated, or hypofractionated with possible combinations
as well. They all try to increase the therapeutic index that
is, the ratio of the probability of tumor control to the
probability of normal tissue toxicity. Published papers in
the head and neck ﬁeld have proved their eﬀectiveness
in comparison to standard fractionation [33, 34]. Particle
radiation therapy has been delivered as well with altered
fractionation schemes taking advantage of its particular
physical and biological properties [35, 36]. When comparing
studies that employed diﬀerent fractionation regimes, it is
useful to refer to the Biologically Eﬀective Dose (BED).
This mathematical formula, BED = nd(1 + d/α/β), [37],
allows comparison of the toxicity or eﬃcacy of diﬀerent
fractionation regimes knowing the number of fractions (n),
the single dose (d), and the α/β ratio that is a radiobiological
parameter that characterizes the response of every tissue to
radiations.
Proton
22 MV X-rays
Spread-out
proton peak
60Co y-rays
22 MeV
electrons 200 kV X-rays
Figure 1: Bragg peak and Spread-Out Bragg Peak (SOBP) for
a proton beam in comparison with photon and electron dose
distributions.
Since particle radiation therapy is not very widespread
and basically still under development, data of its use to treat
sinonasal malignancies are scant.
In this paper we performed a systematic review of the
literature to gather all the clinical experience so far accumu-
lated on this issue focusing on outcome and side eﬀects.
2.MaterialsandMethods
ThePopulation-Interventions-Comparators-Outcomes(PICO)
[38] framework was used to ﬁnd appropriate keywords used
to search the databases. Free text words and Mesh terms for
paranasal sinus malignancies or particle radiation therapy
or outcome or toxicity were generated and then combined
according to Boolean operation “AND” or “OR.” A research
of the literature was carried out in PUBMED and MEDLINE
ﬁrst in August 2011 and then updated in October 2011.
Manual search of the bibliography of pertinent papers was
performed too. Any study known by any author was also
considered for inclusion.
Eligibility criteria were as follows: studies published in
the English language,reporting outcomeand/or toxicity data
on deﬁnitive treatment with particle radiation treatment
of nasal and paranasal sinus malignancies. Studies were
accepted if photon radiation therapy was combined with
particle radiation and if radiation therapy was used either
in deﬁnitive, adjuvant, or neoadjuvant setting. Any use of
chemotherapy was allowed. Studies had to include at least
10 patients and to report data on tumor control and/or
on toxicity. Studies including multiple head and neck sites
were considered and included if it was possible to extract
speciﬁc information on sinonasal malignancies. In case of
publicationswithoverlappingdata,thestudywiththelargest
number and wider data was chosen. Review articles, case
reports, and planning studies were not considered.
Data extracted from publications meeting the eligibility
criteria were ﬁrst author, year of publication, institution,International Journal of Otolaryngology 3
1985 studies excluded as inclusion criteria were not met
27 articles retrieved and reviewed
16 studies excluded
- no speciﬁc data extractable: 2
- updated series: 14
11 clinical studies included
- reporting outcome: 6
- reporting toxicity: 5
2012 citations identiﬁed on
-PubMed: 1226 (including duplicates)
-MEDLINE: 763 (including duplicates)
-Article reference: 18
-Meetings database: 5
Figure 2: Flowchart of the searching process.
number of patients, gender, median age, pathology, stage,
typeofsurgeryreceivedifany,typeofchemotherapyreceived
if any, and followup. Regarding radiation treatment, the
following data were extracted: possible combination with
photon,typeofparticleused,RBEemployed,totaldose,dose
per fraction, number of fractions and number of fractions a
week of the particle used, total dose, dose per fraction,
number of fraction and number of fractions a week of
photons; combined total dose was reported as well. For
studies reporting results on tumor control the following
data were recorded: local, regional and distant control,
overall survival, type, scale and grade of toxicity, time to
toxicity, and risk factors individuated. For studies dealing
particularly with toxicity apart from the available data as
above, the diagnostic criteria used were reported as well as
the maximum dose to aﬀected organs and side eﬀect risk
factors. Any toxicity scale used was also reported.
3. Results
The initial literature research identiﬁed 2012 studies includ-
ing duplicates (see Figure 2). 1985 were excluded after read-
ingthetitleortheabstract,astheydidnotfulﬁlltheinclusion
criteria. Twenty-seven studies remained and were considered
for inclusion. After thorough reading of the full text, two
studies were excluded as speciﬁc data of sinonasal malig-
nancies were not available and fourteen were also excluded
as they have subsequently been updated or because their
data had already been included in other papers with larger
numbers. At the end of the searching process, we identiﬁed
six studies reporting outcome data (see Tables 1, 2, 3)o f
whichtwodealtwithionsandfourwithprotons.Fivestudies
reportingexclusivelytoxicitywerealsoincluded,twoonions,
one on protons, and two on both (see Tables 4, 5).
3.1. Studies Reporting Outcome Data. All the studies report-
ing data on outcome have been published in peer-reviewed
journals apart from the one from Malayapa [39] that has
been presented at the 52nd annual meeting of the American
Society for Radiation Oncology and published in the relative
proceedings.
The ﬁrst publication included in the paper, by Castro et
al. [40], dates back to 1994 and reports results from “The
University of California—Lawrence Berkeley Laboratory.”
Even though the paper deals with skull base malignancies,
speciﬁc data on 22 paranasal and nasal cavity malignancies4 International Journal of Otolaryngology
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were available. All the patients received combined photon
and helium ions radiotherapy for their tumor extending
to the cranial base. Energies used in the synchrocyclotron
were 215/232MeV/u; RBE was 1.3 except for central nervous
system where it was considered to be 1.6. Total dose ranged
from 60 to 80Gy (RBE), median 65Gy (RBE). Further
details on general treatment were not reported. Five-year
actuarial local control and overall survival were 60% and
38%, respectively. Data on toxicity are diﬃcult to extract
since they refer to a wider group of patients with other
malignancies and treated also with neon ions. It would seem
anyhow that the largest amount of toxicity is related to the
use of neon ions.
Mizoe et al. [31] published the results from the NIRS
(National Institute of Radiological Sciences), Heavy Ion
Medical Accelerator in Chiba, Japan. Since 1994, they have
been using carbon ions because of their biologic and physical
characteristics. Carbon ions’ LET and RBE increase with
depth reaching the maximum at the Bragg Peak: here they
show an RBE of 3.0 if compared to photons [41]. Further-
more, experiments have demonstrated that increasing the
carbon ion dose fraction tends to lower the RBE both for
tumor and normal tissues, but more pronouncedly for the
latter [35]. Hypofractionation schemes can be, therefore,
used in carbon ion radiotherapy to increase the therapeutic
ratio. Mizoe et al. [31] report the results of two dose
escalation clinical studies for patients with multiple head
and neck sites. Patients were treated, respectively, according
to a schedule based on 18 fractions in three fractions a
week for six weeks (Group A) or to another based on 16
fractions for four weeks in four fractions a week (Group
B). Doses for each group were escalated every three to ﬁve
patients, in 10% increments starting from 48.6Gy (RBE) for
Group A and from 52.8Gy (RBE) for Group B. Median total
dose for Group A was 59.4Gy (RBE) (range: 48.6–70.2Gy
(RBE)) and 57.6Gy (RBE) (range: 52.8–64.0Gy (RBE)) for
group B. No photons were employed. Acute reactions were
scored according to the RTOG toxicity criteria system, late
to RTOG/EORTC. The Kaplan-Meier local control for both
groups was 49% at ﬁve years. Toxicity was reported for the
entire cohort and no speciﬁc data on sinonasal tumors were
retrievable. Acute Grade (G) 3 skin toxicity was seen in one
Group A patient and in six Group B patients; G3 mucous
membrane toxicity just in one Group B patient. No greater
than G3 toxicity was observed.
Tokuuye et al. [42] from the University of Tsukuba,
Proton Medical Research Center (PMRC), Japan, reported
data of eleven patients with sinonasal malignancies, treated
with protons (four) or with a combination of photons and
protons (seven). They all had inoperable disease or refused
surgery.Mediantotaldose deliveredwas72Gy(RBE)(range:
42–98Gy (RBE)). RBE value was 1.1. Local control was
achieved in nine out of eleven patients and at the moment
of the analysis ﬁve out of eleven patients were alive. One
case of osteoradionecrosis was observed. Again, no speciﬁc
sinonasal toxicity data were distinguishable from that of
other head and neck sites. In the toxicity analysis a trend for
BED(α/β=3) > 130Gy (RBE) was associated with late toxicity
as well as with high fraction size.
Data from Massachusetts General Hospital, Harvard
Cyclotron Laboratory, Francis Burr Proton Center, USA, are
available in the paper of Resto et al. [43] From 1991 to 2002,
102 patients with locally advanced sinonasal malignancies of
varioushistologyreceivedamixedphoton/protontreatment.
Radiotherapy was given as deﬁnitive treatment in 32 cases,
as adjuvant after partial resection in 50, and as adjuvant
after complete resection in 20. Median total dose was 71.6Gy
(RBE); median percentage of protons was 57.1%. Twice-a-
day fractionation schemes were employed in 80% of the
cases. Local control was 95%, 82%, and 87%, respectively,
for patients with complete resection, partial resection, and
biopsy only. Analogously overall survival was 90%, 53%, and
49%, respectively. Regional control and distant metastasis-
free survival were, respectively, 88% and 69%.
Zenda et al. [44] from the National Cancer Center
Hospital East, Chiba Japan, reviewed their results for 39
patients treated with proton radiation therapy. They all had
T4N0M0 unresectable disease of various pathologic types.
A full course of proton therapy, RBE 1.1, was delivered
to a median total dose of 65Gy (RBE) with a median
dose per fraction of 2.5Gy (RBE). Actuarial one-year local
control and ﬁve-year overall survival were 77.0% and 55%,
respectively. Severe acute toxicity was not observed. Late
toxicity G3–5 was reported in 5 patients (12.8%), G5 in 1
patient (2.6%) who suﬀered a CSF leakage.
The University Of Florida Proton Therapy (UFPT)
Institute’s experience is reported in the paper of Malyapa
et al. [39] since January 2007, they have treated 38 patients
with various histotypes of sinonasal malignancies of which
three were in the deﬁnitive setting and 35 in the adjuvant
setting.Positivemarginswerepresentin17casesofthelatter.
Maximum total doses for patients with negative margins
ranged between 68.8 and 69.9Gy (RBE), maximum dose for
patients with positive margins or unresectable disease was
74.4Gy (RBE). In every case, a twice-a-day fractionation
regime was employed: single dose was 1.2Gy (RBE) with
fractions separated each other at least by six hours. At
the moment of the analysis, two in-ﬁeld progressions,
one meningeal seeding, and three distant metastases were
observed. One case of retinopathy within the treated volume
occurred without signiﬁcantly impairing acuity vision.
3.2. Studies Reporting Toxicity Data. A total of ﬁve studies
dealing speciﬁcally with toxicity after particle radiation
therapy were found. Jensen et al. [45] from the University
of Heidelberg, documented exclusively acute toxicity for 29
patients with T4 sinonasal malignancy treated with carbon
ion plus or minus photon radiotherapy to a median dose
of 73Gy (RBE). Accrual period was from November 2009
to August 2010 during which 17 patients received deﬁnitive
treatment, two reirradiations, and nine radiotherapy after
local relapse. Carbon ion total dose was 24Gy (RBE)
delivered in fractions of 3Gy (RBE); IMRT total dose was
50Gy in 25 fractions. Acute toxicity was scored according
to CTCAE versus 4.0. There were no G4 or G5 toxicities
and toxicity related interruption. Mucositis and dysphagia
G3 occurred ﬁve and two times, respectively.10 International Journal of Otolaryngology
Demizu et al. [46], from the Hyogo Ion Beam Medical
Center, Japan, described side eﬀects for 104 patients treated
with carbon ions or protons for their tumor adjacent to optic
nerves. Nasal cavity or paranasal sinuses were involved in
52 cases of which 10 (19.2%) received carbon ions and 42
(80.8%) proton therapy. Carbon ion total dose was 57.6Gy
(RBE) in 16 fractions; proton total dose was 65Gy (RBE) in
18 fractions. Both treatments were administrated ﬁve days
a week. Visual loss resulting from optic neuropathy was
seen at 52 months in one (10%) patient who had received
carbon ions and at a median of 34.5 months in four patients
(9.5%) that had received protons. At univariate analysis age
>60 years, diabetes mellitus and BEDmax > 110Gy (RBE)
(α/β = 3) were observed as possible risk factors. Diabetes
was statistically signiﬁcant at multivariate analysis too.
In the paper of Hasegawa et al. [47], from the National
Institute of Radiological Sciences (NIRS) in Chiba, Japan, 14
patients with paranasal or nasal malignancies that received
proton radiation treatment are included. It was not possible
to retrieve details on other treatments received since they
are described with those of patients with other head and
neck malignancies. Signiﬁcant visual loss was reported in
seven patients (50%), for whom optic nerve sparing had
been diﬃcult due to tumor involvement. Risk factors for
t h ee n t i r eg r o u pa tu n i v a r i a t ea n a l y s i sw e r em a l eg e n d e r ,
chemotherapy, anemia, diabetes mellitus, prescribed tumor
dose, Dmax of the optic nerve >57Gy (RBE), and D10−50.A t
multivariate analysis, D20 > 60Gy (RBE) was still signiﬁcant.
Weber et al. [48] described the visual outcome for
patients treated with accelerated combined proton-photon
radiotherapy for advanced sinonasal malignancies at Mas-
sachusetts General Hospital, Harvard Cyclotron Laboratory,
Francis Burr Proton Center from 1991 to 2001. Given the
demonstrated higher eﬃcacy of altered fractionation regi-
mens towards head and neck malignancies [33], a median
dose of 69.6Gy (RBE) was given to 36 patients twice a day,
with a median fraction size of 1.8Gy (RBE) for protons and
1.6Gy for photons. Percentage of cases treated with protons
ranged between 20% and 84.4%. Complications of the optic
nerves, retina, and lenses were scored according to CTCAE
versus 2.0 scale, of all the others visual organs to LENT.
Grade 3 late toxicity occurred in 2 patients (8.3%), G2 in
6 (16.7%) and G1 in 5 (13.9%). No retinopathy or optic
nerve damage higher than G1 was observed. The reported
5-year probability of higher than G2 toxicity was 20.7% ±
7.8%. Risk factors were GTV dose, age, D50 and D90 to
the optic chiasm, and D10 and D50 to the optic nerve. No
association was found between tumor localization in respect
to the optical apparatus and toxicity.
The experience of The Hyogo Ion Beam Medical Center
about radiation-induced brain injury after proton or carbon
ions is reported in the paper of Miyawaki et al. [49]. Twenty-
eight patients with sinonasal malignancies, out of ﬁfty-nine
of the whole group with head and neck cancers, received
particle radiation therapy either as carbon ions, ﬁve, or
protons, twenty-three. The total dose for the former group
was 57.6Gy (RBE) in 16 fractions of 3.6Gy (RBE), for the
latter was 65Gy (RBE) in 26 fractions of 2.5Gy (RBE).
To compare diﬀerent fractionation schedules they used a
biologically eﬀective dose with α/β value of 3.6. Radiation-
induced brain changes (RIBCs) were evaluated by MRI
ﬁndings on T2-weighted or postcontrast images and graded
according to the LENT-SOMA scale. Related symptoms
were scored according to CTCAE versus 3.0 scale. After a
median interval of 31 (range: 6–49) and 27.5 (range: 19–
36) months, respectively, three patients, treated by protons,
and two by carbon ions developed radiation-induced brain
changes. Radiologic toxicity grades for the three protons-
treated patients were G1, G2, and G3 and for the two carbon
ions-treated patients were G3 and G2. For protons-treated
patients, clinical grading was G1 for one and G2 for two,
meanwhile it was G3 and G1 for the two carbon ions-
treated patients. G3 clinical toxicity consisted of epilepsy
requiring steroids and anticonvulsants. From the analysis
of the whole group, carbon ions were statistically more
frequently associated with RIBCs than protons (P = 0.02).
Minimal median dose to RIBCs sites for the three proton
patients was 117.1Gy (RBE)3 (range: 59.4–117.1Gy (RBE))
and 27.5Gy (RBE)3 (range: 102.4–110.6Gy (RBE)3) for the
two receiving carbon ions. Most of the RIBCs were induced
by doses ≥80Gy (RBE)3, occurring within two years from
radiationincomparisontothoseinducedbylowerdosesthat
developed after two years. Lobe volumes receiving more than
83, 90, and 100Gy (RBE)3 were signiﬁcantly associated with
RIBCs.
4. Discussion
We were able to ﬁnd 11 studies reporting outcome and/or
toxicity results relative to the use of particle radiation
therapy for the treatment of paranasal sinus and nasal
cavity malignancies. There are some common limitations
for these studies that must be emphasized. All but one
study (Mizoe et al. [31]) were retrospective. Six of them
reported data on multiple head and neck sites, and it
was necessary to extract speciﬁc numbers for sinonasal
malignancies. Moreover, they included few patients accrued
over a long period of time. Some studies have a short follow-
up period. Not all the treatments were delivered in dedicated
facilities so that logistic hurdles had to be overcome in
this case [40, 42]. Frequently, various pathologic types are
grouped together even if it is well known that response
to treatment varies among them [4, 20]. Lastly, it was not
always possible to retrieve all the details regarding patients’
general management. Nonetheless, some conclusions from
the available data can be made.
Heavy particle radiotherapy is in its early phase of
development, and it is mainly employed for unresectable
or high-risk cases. This type of radiation therapy combined
with photons or not is feasible and well tolerated by
patients either as deﬁnitive or as adjuvant treatment. The
delivery of the prescribed dose was possible in all studies,
and all patients could complete their treatment. Altered
fractionation schemes were safely employed to increase the
therapeutic ratio [31, 39, 44, 48], but other studies [42, 49]
found that late radiation toxicity can be related to the high
single fraction dose.International Journal of Otolaryngology 11
Local control rates compare positively with those from
Institutions that used photon radiation therapy (Table 6).
L o c a lc o n t r o lr a t e sa t5y e a r sa c h i e v e dw i t hc o n f o r m a l
photon radiotherapy are around 62%–84% [20, 52] for the
postoperative setting and around 21%–43% [10, 21]f o r
deﬁnitive treatment. Resto et al. [43] showed local control
rates at 5 years according to extent of resection that were
95%,82%,and87%forcompleteresection,partialresection,
and biopsy only, respectively. At univariate analysis, these
ﬁgures did not diﬀer signiﬁcantly (P = 0.32). Castro et al.
[40] reported a 5 year local control rate of 60%; Zenda et
al. [44] had one-year local control of 77%, for 39 patients
with locally advanced disease. Malyapa et al. [39] at the
moment of the analysis reported that 36 out of 38 patients
were free of local disease; for Tokuuye et al. [42], 9 out of 11
patients were free of local recurrence. The apparently lower
local control rate from Mizoe et al. [31] must be taken into
account cautiously considering that it was a Phase I/II study
whose main purpose was to determine the normal tissue
tolerance dose. Indeed some of the patients were given a dose
that was thought to be 80% of the radical dose needed for
advanced head and neck cancers. Interestingly, in the study
of Resto et al. [43] local control was found to be independent
from the extent of resection. Rates of distant metastasis free-
survival and overall survival were signiﬁcantly diﬀerent in
caseofcompleteresection,95%and90%,respectively,versus
partial, 69% and 53%, respectively, or biopsy only, 52% and
49%, respectively (P = 0.03, P = 0.02).
In general, for particle radiation therapy studies, rates
of distant metastasis free-survival and overall survival are
not substantially diﬀerent from other studies. Obviously, this
means that an eﬃcient systemic therapy capable of dealing
with metastasis is needed for particle therapy too.
Regional control is reported in the papers of Resto et al.
[43] and Zenda et al. [44] only. Details of neck treatment
arenotreportedextensively;regionalcontrolratesaresimilar
being 88% and 87.2%, respectively, conﬁrming that regional
failures are quite infrequent in this disease.
Acute toxicity seems to be mild, well tolerated, and
does not interfere with treatment delivery as pointed out
in the speciﬁc paper by Jensen et al. [45]. Late toxicity
was not reported extensively by all studies of the group
reporting data on outcome. Mizoe et al. [31]r e p o r t e dn o
l a t et o x i c i t y ;T o k u u y ee ta l .[ 42]r e p o r t e dj u s to n ec a s e
of osteoradionecrosis. The only G5 toxicity was described
by Zenda et al. [44], which was due to CSF leakage. Late
toxicity was speciﬁcally reviewed in four papers, three of
them dealing with visual side eﬀects and one with CNS side
eﬀects. Median time to the onset of visual side eﬀects ranged
between 24 and 52 months. In the study of Weber et al.
[48], higher doses were associated with faster development
of side eﬀects, analogously to what already described by
other authors [53]. Radiation-induced optic neuropathy
leading to severe visual loss occurred in ﬁve out of ﬁfty-
two (9.6%) and in seven out of fourteen (50%) patients
for the studies of Demizu et al. [46] and Hasegawa et al.
[47], respectively. The latter ﬁgure may seem high, but it
is to note that all the optic nerves showing high-grade
toxicity had been invaded by the tumor making it almost
impossibletosparethem.ThenegativeeﬀectofthehighRBE
of carbon ions cannot be completely ruled out though. The
result by Demizu et al. [46] seems acceptable considering
the particular location of disease and when compared to
other data. Jiang et al. [54] reported blindness due to optic
neuropathy in 8 out of 98 (8.1%) evaluable patients who had
received radiation therapy for sinonasal malignancies. In a
previous publication from Massachusetts General Hospital,
Habrand et al. [55]r e p o r t e dd a t ao nn e u r o v i s u a lo u t c o m e
after proton radiotherapy for upper clivus malignancies; two
patientsoutofﬁfteen(13.3%)developedvisualdeterioration
at 10 and 36 months, respectively. This was due to optic
nerve and optic chiasm damage in one and to bilateral optic
nerve damage in the other. Results from the study of Weber
et al. [48] are encouraging, being that any type of visual
toxicity ≥G2 is around 20%. In fact, they only had two G3
complications out of thirty-six patients (8.3%), namely, a
cataract and a nasolacrimal duct blockage. Jiang et al. [54]
described a total of 60 ipsilateral visual events in 178 patients
treated(33.8%);sevenofthemexperiencedalsocontralateral
visual impairment.
Among the possible risk factors, all the studies of particle
radiation therapy found important the maximum dose
delivered. This conﬁrms both the concept that many optic
structures are serial organs and the results from previous
studies. Parsons et al. [22] observed indeed no injuries in
131 patients with head and neck malignancies if their optic
nerves were irradiated to less than 59Gy. Jiang et al. [54]
in their study about 219 individuals with cancers of the
nasal cavity and paranasal sinuses found that the radiation
dose was the predominant determinant for optic nerves
and optic chiasm injury with no patient receiving less than
50Gy showing any impairment. Analogously, Takeda et al.
[56] did not observe any retinal complications for patients
receiving less than 50Gy. Habrand et al. [55] suggested a
threshold value of 55Gy (RBE) associated with a 10% major
complication rate. Urie et al. [57] found as well that the dose
is a signiﬁcant predictor of cranial nerve injury but with a
value of 70Gy (RBE) that is higher than what is commonly
reported.
A volume factor for the irradiated OAR has been
individuated as risk factor in the study of Hasegawa et al.
[47]. The dose to the 20% of the optic nerve higher than
60Gy (RBE) was signiﬁcantly associated with visual loss at
multivariate analysis. This is in accordance with the ﬁndings
of Weber et al. [48] that reported partial OAR volume
irradiation as a risk factor even if they pointed out that setup
uncertainties and contouring variability may confound data.
Takeda et al. [56] found as well that irradiated retina area
correlates with the incidence of sever late complication.
D r y - e y es y n d r o m ei sas e r i o u ss i d ee ﬀect associated with
head and neck radiotherapy [53]. In this regard, the study
of Weber et al. [48] showed a low incidence rate of serious
toxicity since they were able to deliver to the lachrymal appa-
ratus a dose below the generally accepted threshold value of
30Gy [53]. Furthermore, their good results may be related to
the use of a twice-a-day fractionation schedule. Monroe et al.
[58] studying 186 patients with head and neck malignancies
found that a twice-a-day hyperfractionation schedule with12 International Journal of Otolaryngology
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single doses between 1.1 and 1.2Gy, separated at least by
4h–6h, was signiﬁcantly associated with lower incidence of
retinopathy. The same group (Bhandare et al. [59]) observed
that also optic neuropathy may be reduced with the same
schema.ThisisinaccordancealsowiththereportofMalyapa
et al. [39] that described just one case of mild retinopathy
for a group of patients treated with hyperfractionated proton
therapy. As regards to hypofractionation, Parsons et al. [60]
showed that the use of larger fraction size is associated with
retinal toxicity. In the study of Demizu et al. [46], single
fraction was 3.6Gy (RBE) for carbon ions and 2.5Gy (RBE)
for protons and they did not raise particular concern about
the utilization of high-dose per fraction.
Other risk factors found by the speciﬁc studies were
diabetes mellitus that has already been associated with
toxicity by other authors [59, 61] and age where data from
published experience are not deﬁnitive [22, 58, 59]. The
study of Weber et al. [48] has the apparently paradox ﬁnding
that younger age is linked with higher toxicity. This may
be explained with the longer follow-up period elapsed for
this group of patients. Data on the use of chemotherapy are
not deﬁnitive: it is positively related to toxicity at univariate
analysisinthestudyofHasegawaetal.[47]butnotforW eber
et al. [48], Bhandare et al. [59], and Takeda et al. [56].
Brain late side eﬀects have always been among the
most dreaded consequences of radiation therapy. Signiﬁcant
neurologic alterations have been described in association
with photon and particle radiotherapy for paranasal and
nasal cavity malignancies [23, 62]. The study of Miyawaki et
al.[49]hasa goodtoxicity proﬁlewith justone patient out of
28 experiencing G3 brain toxicity, that is, epilepsy requiring
medical treatment. Factors related to toxicity were dose
≥80Gy (RBE)3 and volumes of cerebral lobe receiving more
than 83, 90, and 100Gy (RBE)3. Maximum dose and volume
receiving a given dose are recognized risk factors for brain
toxicity. From the review of published data, Lawrence et al.
[63] could conclude that the incidence and severity of brain
side eﬀects is dose and volume dependent. Brain necrosis
incidence of 5% occurs for BED(α/β= 3) = 120Gy, if stan-
dard fractionation regimes are employed. Experiences with
singlefractionradiosurgeryclearlydemonstrateacorrelation
between target size and side eﬀects. The study of Debus et al.
[64] about 367 patients receiving photon/proton radiation
therapy for skull base chordoma and chondrosarcoma found
a 10-year brainstem toxicity-free survival of 88%; risk factors
at multivariate analysis were diabetes, number of surgical
procedures, and volume of brainstem receiving 60Gy (RBE)
(P<0.001). Schlampp et al. [65] observed 10 temporal
lobe reactions at MRI out of 59 patients treated with
carbon ions for chordoma and chondrosarcoma of the skull
base. Most important predictors of toxicity were age and
maximum dose applied to at least 1cm3 of the temporal
lobe. Carbon ions were found by Miyawaki et al. [49]t ob e
signiﬁcantly more frequently associated than protons with
brain toxicity. According to the author, a reason could be
found in the diﬀerent fractionation schedules employed:
single-fraction carbon ion dose of 3.6Gy (RBE) would be
more toxic than a proton one of 2.5Gy (RBE). Some studies
in the literature support this hypothesis as, for example,
the report of Lee et al. [66] about 1008 patients treated for
nasopharyngeal carcinoma: signiﬁcantly higher incidence of
temporal lobe necrosis was associated with single fraction
size of 4.2Gy. Lawrence et al. [63] in their review could not
make any deﬁnitive conclusion about incidence and severity
of toxicity when fractionated radiation therapy with single
doses>2.5Gyisused.Alsointhiscase,theeﬀectofthehigher
RBE of carbon ion cannot be ruled out deﬁnitely.
5. Conclusions
Particle radiation therapy is a promising tool for the
treatment of paranasal and nasal cavity malignancies. Con-
sidering that it is in its early phases of development, it has
shown to be feasible and well tolerated. Results regarding
local control are encouraging and late toxicity is acceptable.
Further research is needed to establish its exact role and its
best combination with surgery and chemotherapy.
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